UnknownPhase 2NCT03704181
Colchicine for Patients With Chagas´ Disease( B1 Stage)
Studying American trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Sao Paulo General Hospital
- Principal Investigator
- Fabio Fernandes, Md, PHD, M.DHeart Institute, University of São Paulo
- Intervention
- Colchicine 0.5 MG twice day for one year(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2018 – 2021
Study locations (1)
- Fabio Fernandes, São Paulo, Brazil
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03704181 on ClinicalTrials.govOther trials for American trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06632600A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Novartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07033325University-Based Chagas Testing in Salta Province, ArgentinaMundo Sano Foundation
- RECRUITINGPHASE3NCT04897516Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas DiseaseLaboratorio Elea Phoenix S.A.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04984265SBRT in Chagas Disease Ventricular TachycardiaUniversity of Sao Paulo General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT04024163Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas DiseaseInsud Pharma